NASDAQ · Biotechnology

Cytokinetics, Incorporated (CYTK) Stock

$61.23 -1.76% NASDAQ: CYTK Healthcare

Valuation

Metric	Value
Price	$61.23
Market Cap	$8.51B
P/E Ratio	-8.72
P/B Ratio	-47.86
P/S Ratio	123.15
EPS (TTM)	$0.00
52-Week High	$88.31
52-Week Low	$54.30
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	163.98%
ROA	-46.45%
ROCE	-40.42%
Gross Margin	-695.45%
Operating Margin	-695.45%
Net Margin	-784.02%
Debt/Equity	-7.32
Current Ratio	4.54

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$70.0M	$95.0M	$8.0M	$18.0M	$88.0M
Operating Profit	$-186.0M	$-324.0M	$-496.0M	$-536.0M	$-612.0M
Net Profit	$-215.0M	$-389.0M	$-526.0M	$-590.0M	$-785.0M
EPS	$-2.80	$-4.33	$-5.45	$-5.26	$-6.54
Op Margin	-264.5%	-342.8%	-6589.7%	-2902.7%	-695.4%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$841.0M	$1.0B	$824.0M	$1.4B	$1.4B
Total Liabilities	$597.0M	$1.1B	$1.2B	$1.5B	$2.1B
Cash	$113.0M	$66.0M	$113.0M	$95.0M	$123.0M
Borrowings	$270.0M	$750.0M	$756.0M	$789.0M	$1.3B

Latest News

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy Zacks · Jul 15, 2026 Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet Zacks · Jul 15, 2026 CYTK: Lowering target price to $86.00 Argus Research · Jul 15, 2026 What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% Motley Fool · Jul 14, 2026 Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing MT Newswires · Jul 14, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-143.0M	$-300.0M	$-414.0M	$-396.0M	$-510.0M
Investing Cash Flow	$-197.0M	$-273.0M	$238.0M	$-557.0M	$-8.0M
Financing Cash Flow	$8.0M	$164.0M	$58.0M	$233.0M	$-2.0M
Net Cash Flow	$30.0M	$-45.0M	$46.0M	$-18.0M	$30.0M
Free Cash Flow	$-191.0M	$-311.0M	$-416.0M	$-400.0M	$-535.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.26
EV / EBITDA	-11.87
FCF Yield	-6.65%
Quick Ratio	6.66
Interest Coverage	-5.64
Return 1Y	1.17%
Return 3Y	100.49%
Return 5Y	57.92%

Ownership

Insiders Held0.67%

Institutions Held118.82%

Institutions Float Held119.62%

Institutional Holder	Shares	Report Date
T. Rowe Price Investment Management, Inc.	17,523,840	2026-03-31
Blackrock Inc.	16,548,011	2026-03-31
FMR, LLC	10,723,140	2026-03-31
Wellington Management Group, LLP	8,009,489	2026-03-31
Vanguard Portfolio Management LLC	5,843,782	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BCDABioCardia, Inc.	$0.92	-0.83%	-1.54	$13.94M	0.00%
BRVEBraveheart Bio, Inc.	$21.44	-0.19%	-21.64	$1.51B	0.00%
KARDKardigan, Inc.	$12.80	+0.47%	-5.98	$1.14B	0.00%
RNAAtrium Therapeutics, Inc.	$8.20	+0.49%	-2.13	$140.27M	0.00%
TNYATenaya Therapeutics, Inc.	$0.39	+0.26%	-1.06	$87.23M	0.00%

About Cytokinetics, Incorporated

Cytokinetics, Incorporated is led by CEO Robert I. Blum, employs 673 people, headquartered in South San Francisco, US, publicly traded since 2004.

Cytokinetics, Incorporated (CYTK) stock trades at $61.23 with a market capitalization of $8.51B. The stock is valued at a negative price-to-earnings (P/E) ratio of -8.72, reflecting a net loss over the last twelve months, a negative price-to-book of -47.86, reflecting negative shareholders' equity, price-to-sales of 123.15. Over the past 52 weeks the stock has ranged between $54.30 and $88.31, and currently trades 30.7% below its 52-week high.

On profitability, Cytokinetics, Incorporated generates a return on equity (ROE) of 163.98% (not meaningful, as shareholders' equity is negative), return on capital employed of -40.42%, an operating margin of -695.45%, a net profit margin of -784.02%.

Cytokinetics, Incorporated by the numbers, 2016–2025

Between 2016 and 2025 Cytokinetics, Incorporated reported revenue of $106.0M rising to $88.0M, a change of -17.0% across 10 years. Compounded, revenue has grown 9.5% a year over five years, -2.5% over three, 388.9% over the last twelve months. Net profit fell to $-785.0M.

Operating margin went from 17.6% in 2016 to -695.4% in 2025, a fall of 713.0 percentage points. The most recent net margin is -784.02%. On a trailing twelve-month basis to Jun '26, revenue is $71.0M and net profit $-894.0M.

Borrowings rose from $27.0M to $1.3B, cash from operations was $-510.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged 192.9% over five years, and was 118.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Cytokinetics, Incorporated (CYTK) — frequently asked questions

What is Cytokinetics, Incorporated (CYTK) stock price today?

Cytokinetics, Incorporated (CYTK) is currently trading at $61.23, down 1.76% today.

What is CYTK P/E ratio?

Cytokinetics, Incorporated's P/E ratio is -8.72. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is CYTK return on equity (ROE)?

Cytokinetics, Incorporated's return on equity (ROE) is 163.98%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is Cytokinetics, Incorporated's market cap?

Cytokinetics, Incorporated has a market capitalization of $8.51B.

Does CYTK pay a dividend?

Cytokinetics, Incorporated is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does CYTK carry?

Cytokinetics, Incorporated has a debt-to-equity ratio of -7.32. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is CYTK's profit margin?

Cytokinetics, Incorporated reports a net profit margin of -784.02% — the share of revenue left after every cost, including tax and interest.

What sector is CYTK in?

Cytokinetics, Incorporated is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is CYTK listed on?

Cytokinetics, Incorporated trades on NASDAQ under the ticker CYTK.

What is CYTK's 52-week range?

Over the last year Cytokinetics, Incorporated has traded between $54.30 and $88.31.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Screens CYTK currently matches

On the figures above, Cytokinetics, Incorporated passes the filters for 8 of our ready-made screens, among them High ROE Stocks, Low Debt Stocks, Companies With Highest ROE. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

High ROE Stocks Low Debt Stocks Companies With Highest ROE Low Debt High ROE Stocks Stocks Under $100 Mid Cap Stocks High ROE Stocks Under $100 High Current Ratio Stocks

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.